Actively Recruiting
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Led by University of Southern California · Updated on 2026-03-27
30
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
University of Southern California
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
CONDITIONS
Official Title
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- ECOG performance status of 2 or less
- Ability to understand and willing to sign informed consent
- Diagnosed with polycythemia vera, essential thrombocytosis, or myelofibrosis according to WHO 2016 criteria
- Presence of at least one symptom with severity greater than 3 measured by MPN-Symptom Assessment Form
- Stable disease unlikely to require new cytoreductive therapy during the study; stable hydroxyurea dose for at least 6 months allowed
- Diagnosed with clonal cytopenia of undetermined significance (CCUS) or low risk myelodysplastic syndrome (LR-MDS)
- CCUS defined as persistent cytopenia for more than 6 months with specific blood count thresholds, normal cytogenetics, detectable MDS-associated mutations, and bone marrow morphology not diagnostic of MDS or other malignancies
- LR-MDS diagnosis according to WHO 2016 criteria
- Minimum baseline fatigue symptom score of 25 on the symptom questionnaire
You will not qualify if you...
- Current intake of curcumin dietary supplements or unwillingness to stop more than 24 hours before study
- Inability to understand or adhere to study information
- Receiving active treatment for another malignancy except hormonal therapy in remission or certain growth factors
- Intermediate or high-risk myelodysplastic syndrome
- Pregnant or nursing women
- Use of oral or intravenous steroids or other anti-inflammatory drugs above specified dose limits (ibuprofen > 200mg/week or 400mg/month, any naproxen, aspirin > 325mg daily, or herbal anti-inflammatory concoctions)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Los Angeles General Medical Center
Los Angeles, California, United States, 90033
Actively Recruiting
2
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
Research Team
C
Christine Duran
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here